{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field bb219242-7eb7-4a5a-a53f-0e1784ca10f3 --><h2>What else might it be?</h2><!-- end field bb219242-7eb7-4a5a-a53f-0e1784ca10f3 -->","summary":"","htmlStringContent":"<!-- begin item c93266f8-7171-4921-999e-582ee0402dd9 --><!-- begin field 4add2baf-6d35-48b2-8a25-b0f9dd4d3ae1 --><ul><li><strong>Common conditions that present with unilateral redness and/or swelling include:</strong><ul><li>Deep venous thrombosis — characterized by pain and swelling of the calves without significant erythema. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/deep-vein-thrombosis/\">Deep vein thrombosis</a>.</li><li>Septic arthritis — involvement of the joint and disproportionate pain with joint movement.</li><li>Acute gout — swelling, redness, warmth, and pain on passive movement. The skin around the joint may be inflamed. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gout/\">Gout</a>.</li><li>Ruptured Baker's cyst — may cause unilateral calf swelling.</li><li>Thrombophlebitis — venous inflammation with thrombus formation. May cause redness, inflammation, and pain. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/\">Thrombophlebitis - superficial</a>.</li><li>Cutaneous abscess — a hot, red, swollen and painful swelling, which may need incision and drainage.</li><li>Erysipelas — a form of cellulitis involving more superficial dermal structures distinguished clinically by raised and well demarcated borders.</li></ul></li><li><strong>Chronic conditions </strong>(these are usually bilateral but if worse on one side, it may be difficult to exclude superimposed cellulitis):<ul><li>Varicose eczema/venous insufficiency — crusting, scaling, and itching.</li><li>Contact allergic dermatitis — can present acutely as erythematous, sore and tender areas of skin, sometimes with blisters. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dermatitis-contact/\">Dermatitis - contact</a>.</li><li>Lipodermatosclerosis — a painful, red, tender, warm, hard, and sometimes scaly rash that occurs in the absence of significant systemic upset. It is most likely to occur in the lower leg in obese women with venous insufficiency. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/\">Venous eczema and lipodermatosclerosis</a>.</li><li>Cutaneous small vessel vasculitis — palpable purpura typically on the lower legs and ankles.</li><li>Lymphoedema — swelling (especially in the subcutaneous tissues) that occurs as a result of excess accumulation of lymph due to inadequate drainage.</li><li>Oedema with blisters.</li><li>Panniculitis — inflammation of subcutaneous adipose tissue.</li></ul></li><li><strong>Other conditions include:</strong><ul><li>Drug reaction — characterized by itching and burning. There is usually a well-demarcated area of involvement and a history of similar reaction with prior exposure to the same drug.</li><li>Necrotizing fasciitis — a destructive and rapidly progressive soft tissue infection that involves the deep subcutaneous tissues, fascia, and occasionally muscles. The presenting signs are usually non-specific (redness, swelling, and pyrexia). The person is usually systemically very unwell and has disproportionate pain.</li><li>Metastatic cancer (carcinoma erysipeloides) — a fixed, red patch often with a raised edge and oedema due to lymphatic obstruction. A metastasis from breast cancer is the most common cause, but rarely it may be caused by lung, ovarian, colonic, or pancreatic metastases, or malignant melanoma.</li><li>Wet gangrene — ischaemia of tissue with adjacent cellulitis due to putrefaction of dead tissue.</li><li>Erythema nodosum — painful, red, warm nodules and plaques on the shins, knees, and ankles.</li><li>Pyoderma gangrenosum — small, tender pustules or papules that ulcerate with a purple undermined edge and surrounding redness, typically on the trunk or legs.</li><li>Eosinophilic cellulitis (Wells syndrome) — presents with large, indurated erythematous plaques, and less commonly nodules, that evolve over several weeks. Most people have a blood eosinophilia.</li><li>Eosinophilic fasciitis — the acute inflammatory stage consists of pain, swelling, and tenderness of the distal limbs. These findings are later replaced by induration, and eventually fibrosis with limitation of the movement of the hands and feet. The affected skin is taut and firmly adherent to underlying tissue with dimpling and a peau d'orange appearance. The condition has a symmetrical distribution, and there is a blood eosinophilia in 70% of cases.</li></ul></li></ul><!-- end field 4add2baf-6d35-48b2-8a25-b0f9dd4d3ae1 --><!-- end item c93266f8-7171-4921-999e-582ee0402dd9 -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7305e6df-9b2c-5584-9412-54564432e382","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"8011efe0-d86e-5717-a7bc-b96ae353e289","slug":"basis-for-recommendation-463","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field d05eb05d-5a9d-4293-b2da-2916dbf89145 --><h3>Basis for recommendation</h3><!-- end field d05eb05d-5a9d-4293-b2da-2916dbf89145 -->","summary":null,"htmlStringContent":"<!-- begin item 4630fbd1-09b0-4c48-bff6-2d79400d6803 --><!-- begin field de786c2f-ccc3-4ace-95bd-17a71d263253 --><p>The information on differential diagnoses is based on the Clinical Resource Efficiency Support Team (CREST) <em>Guidelines on the management of cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Cellulitis, erysipelas, and necrotising fasciitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PCDS, 2018</a>], review articles on cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Stevens et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Gunderson, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Shriner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Bystritsky, 2018</a>], and information in a medical dictionary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Pugh, 2000</a>].</p><!-- end field de786c2f-ccc3-4ace-95bd-17a71d263253 --><!-- end item 4630fbd1-09b0-4c48-bff6-2d79400d6803 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}